MedTrace Logo

Physical Activity Intervention for MPS

NCT07449143 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-08-19

No results posted yet for this study

Summary

Currently, treatments for mucopolysaccharidoses (MPS) are pharmacological and predominantly focus on the physical symptoms of the disease. In the general population and individuals with disabilities, increasing physical activity levels and reducing sedentary time can be an effective, non-pharmacological treatment to improve mental health and quality of life. Such interventions have not yet been developed or evaluated in people with MPS.

The aim of this study is to co-design a physical activity and sedentary behaviour intervention tailored to the needs of adults with MPS. The study will seek to gain the expertise of adults with MPS, specialist stakeholders (physicians and clinical nurse specialists) and lay specialist stakeholders (family and friends of adults with MPS and members of staff and volunteers at the Society for Mucopolysaccharide Diseases). A range of views and experiences of physical activity and sedentary behaviour will be explored via focus groups (with individuals with MPS and lay specialist stakeholders) and semi-structured interviews (with specialist stakeholders). The information gathered from the focus groups and interviews will then be utilised to inform participatory workshops (with individuals with MPS) to test intervention concepts. Data from these activities will inform the design of a future intervention.

Conditions

  • Mucopolysaccharidosis (MPS)

Interventions

OTHER

Interviews/focus groups/participatory workshops

Qualitative study (no intervention delivered)

Sponsors & Collaborators

  • University College London Hospitals

    collaborator OTHER

  • Northern Care Alliance NHS Foundation Trust

    collaborator OTHER

  • Royal Free Hospital NHS Foundation Trust

    collaborator OTHER

  • Brunel University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449143 on ClinicalTrials.gov